Envisagenics, a biotechnology company based in New York, is at the cutting edge of RNA therapeutics development. They have developed a unique platform called SpliceCore® that leverages RNA sequencing data and artificial intelligence/machine learning algorithms to identify, test, and validate drug targets with greater speed and precision than traditional methods.
This platform not only identifies new targets but also explains the mechanism by which the antisense drugs regulate the splicing event, leading to more transparent and verifiable AI/ML predictions.
Envisagenics was founded by a team of experts in the field of RNA splicing and has received funding from various investors, including the National Institutes of Health. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.